OncoResponse
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
609 Main St Ste 4200, Houston, Texas, 77...Phone Number
(206) 805-1600Website
www.oncoresponse.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About OncoResponse
OncoResponse is leveraging the company's proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancer and extending cures to the greatest number of patients who otherwise would not respond to immunotherapy.Explore more
OncoResponse Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoResponse your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once OncoResponse has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when OncoResponse launches new products
Check if OncoResponse has recently received funding, and reach out quickly before it becomes old news!
Check out if OncoResponse is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if OncoResponse had a recent Job posting/layoffs
OncoResponse, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at OncoResponse
Earning: See what the market has to say on OncoResponse recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to OncoResponse
Compare insights from companies similar to OncoResponse, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OncoResponse is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OncoResponse is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OncoResponse.
OncoResponse financials insights
Gather financial insights about OncoResponse, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$29.5M
Series A
$9.5M
2018
Series B
$40M
2020
Debt
$150K
2021
Debt
$416K
Series C
$40.6M
2022
Debt
$50M
2023
Grant
$13M
Other Financing Round
$14M
2025
Other Financing Round
$6M
OncoResponse Tech Stack
A closer look at the technologies used by OncoResponse
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
Executive Move
Board of Directors
Funding
Funding
OncoResponse News & Media
OncoResponse Announces Phase 1 Results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
- Late-Breaker Poster Presentation to occur at the 39th Annual Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2024 - - Ongoing study to evaluate OR502 as monotherapy and in combination with anti-PD-1 therapy - HOUSTON, Nov. 7, 2024 /PRNewswire/ -- OncoResponse, a...OncoResponse to Present Phase 1 Results of Clinical Study of OR502, anti-LILRB2 Antibody, as a Late-Breaker Poster Presentation at SITC 2024
HOUSTON, Nov. 4, 2024 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced that it will present Phase 1 results for the clinical study of OR502, a novel, humanized...ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA’s proprietary B Cell Select® platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPOncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
- Study to evaluate OR502 as monotherapy and in combination with anti-PD-1 therapy - SEATTLE, Nov. 29, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the dosing of...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding OncoResponse
Sign Up For FreeTo access detailed company insights
OncoResponse is leveraging the company's proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancer and extending cures to the greatest number of patients who otherwise would not respond to immunotherapy.... Read More
